1. Home
  2. ALLT vs SLDB Comparison

ALLT vs SLDB Comparison

Compare ALLT & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allot Ltd.

ALLT

Allot Ltd.

N/A

Current Price

$7.01

Market Cap

519.6M

ML Signal

N/A

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

N/A

Current Price

$7.95

Market Cap

498.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALLT
SLDB
Founded
1996
2013
Country
Israel
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
519.6M
498.6M
IPO Year
2006
2017

Fundamental Metrics

Financial Performance
Metric
ALLT
SLDB
Price
$7.01
$7.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$12.25
$14.70
AVG Volume (30 Days)
672.8K
1.2M
Earning Date
01-01-0001
06-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
36.65
EPS
N/A
N/A
Revenue
N/A
$8,094,000.00
Revenue This Year
$14.86
N/A
Revenue Next Year
$12.10
N/A
P/E Ratio
$469.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.37
$2.45
52 Week High
$11.92
$7.37

Technical Indicators

Market Signals
Indicator
ALLT
SLDB
Relative Strength Index (RSI) 32.82 68.05
Support Level $6.20 $5.08
Resistance Level $8.20 N/A
Average True Range (ATR) 0.59 0.45
MACD -0.17 0.11
Stochastic Oscillator 19.10 95.35

Price Performance

Historical Comparison
ALLT
SLDB

About ALLT Allot Ltd.

Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Share on Social Networks: